BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma

Melanoma Res. 2014 Aug;24(4):415-8. doi: 10.1097/CMR.0000000000000088.

Authors

Celeste Lebbé¹, Alexandre How-Kit, Maxime Battistella, Aurelie Sadoux, Marie-Pierre Podgorniak, Irina Sidina, Cécile Pages, Jennifer Roux, Raphael Porcher, Jorg Tost, Samia Mourah

Affiliation

¹ aAP-HP, Department of Dermatology, Saint-Louis Hospital bParis-Diderot University, Sorbonne Paris Cite cINSERM U976 dLaboratory for Functional Genomics, Jean Dausset Fondation - CEPH eAP-HP, Pathology Laboratory, Saint-Louis Hospital, INSERM UMR_S 1165 fAP-HP, Saint-Louis Hospital, Pharmacology-Genetic Laboratory gDepartment of Biostatistics and Medical Data Processing, INSERM-U717 hLaboratory for Epigenetics and Environment, Genotyping National Center, CEA, Genomic Institute iINSERM UMR-S 940, Paris, France.

PMID: 24933605
DOI: 10.1097/CMR.0000000000000088

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Disease Progression
Female
Humans
Indoles / adverse effects
Indoles / therapeutic use*
Male
Melanoma / drug therapy*
Melanoma / enzymology
Melanoma / genetics
Mutation*
Neoplasm Metastasis
Proto-Oncogene Proteins B-raf / genetics*
Proto-Oncogene Proteins B-raf / metabolism
Skin Neoplasms / drug therapy*
Skin Neoplasms / enzymology
Skin Neoplasms / genetics
Sulfonamides / adverse effects
Sulfonamides / therapeutic use*
Treatment Outcome
Vemurafenib

Substances

Antineoplastic Agents
Indoles
Sulfonamides
Vemurafenib
BRAF protein, human
Proto-Oncogene Proteins B-raf